History_CHIGENOVO Co., Ltd. Drug development|Ophthalmic diseases

中文 /EN

400-6006223

NEWS CENTER

2024-07

2016

CHIGENOVO was founded to provide one-stop solutions for the diagnosis and treatment of inherited eye diseases

2024-07-01

2024-07

2018

Received angel investment and initiated the productization process of ophthalmic gene therapy

2024-07-01

2024-07

2020

Received Pre-A investment to accelerate the commercialization processes of pipelines

2024-07-01

2024-07

2021

ZVS101e injection received FDA orphan drug designation and started clinical trials

2024-07-01

2024-07

2022

Received A-round investment to accelerate project R&D and clinical trials ZVS101e injection obtained IND approvals from China NMPA and U.S. FDA ZVS203e injection received FDA orphan drug designation

2024-07-01

2024-07

2023

Received A+ round investment The Phase I/II clinical trial of ZVS101e injection was completed for all participants ZVS203e injection started IIT clinical trial and submitted IND application in US and China ZVS203e injection obtained IND approvals from the U.S. FDA

2024-07-01

2024-07

2024

ZVS203e injection obtained IND approvals from China NMPA ZVS101e injection received Breakthrough Therapy designation from China NMPA Initiated ZVS101e phase III clinical trial

2024-07-01

< 1 >

CHIGENOVO Co., Ltd. is an ophthalmic gene therapy company, a national high-tech enterprise focusing on genetic diagnosis of genetic eye diseases and the development of gene therapy drugs. It is committed to providing "one-stop" services for patients with genetic eye diseases.

Telephone:400-6006223 010-82071936
Website:en.chinagene.cc
Address: Floor 4, Area D, Building 1, No.27 Life Garden Road, Zhongguancun Life Science Park, Changping District, Beijing

WeChat subscription account

Business License

NEWS CENTER

HUATAO GROUP